Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.72 |
| ▸ | HLCS | P50747 | 2/20 | 0.70 |
| ▸ | CNR1 | P21554 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | IDE | P14735 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240579 | 1.00 | TDP1 (0.72) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL17704089 | 1.00 | TDP1 (0.72) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL13045403 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL15870672 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL22493325 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL12320610 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL7376597 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL12729936 | 0.99 | HLCS (0.71) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL13621820 | 0.97 | TDP1 (0.70) | TDP1HLCSCNR1MEN1ABL1 | |
| SCHEMBL14600797 | 0.97 | TDP1 (0.70) | TDP1HLCSCNR1MEN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183654-A1 | METHOD FOR SELECTING HYBRIDOMA CELLS FROM A PLURALITY OF HYBRIDOMA CELLS BY MEANS OF A BIRA EXPRESSION VECTOR | new/era/mabs GmbH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-7943595-B2 | Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative | SANOFI-AVENTIS (FR) | 2011-05-17 | — | — | US | disclosed |
| EP-0956363-B1 | METHOD OF DETERMINING THE ENZYMATIC ACTIVITY OF THE BLOOD COAGULATION FACTOR XIII USING PURIFIED FIBRIN MONOMER AS A SUBSTRATE | GREEN CROSS KOREA (KR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1346730-A1 | Pretargeting methods and novel pretargeting conjugates | NEORX CORPORATION (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6406874-B1 | FORMING A FIBRIN CLOT, DETECTION CROSSLINKING IN CLOT | KOREA GREEN CROSS CORPORATION (KR) | 2002-06-18 | — | — | US | disclosed |
| US-6217869-B1 | ADMINISTERING ANTIBODY, ANTIGEN, LIGAND COMPLEX | NEORX CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6015897-A | FOR CONJUGATION TO LIGAND/ANTILIGAND PAIR AND USE IN DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENT TO TARGETED SITE | NEORX CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| EP-0956363-A1 | METHOD OF DETERMINING THE ENZYMATIC ACTIVITY OF THE BLOOD COAGULATION FACTOR XIII USING PURIFIED FIBRIN MONOMER AS A SUBSTRATE | KOREA GREEN CROSS CORPORATION (KR) | 1999-11-17 | — | — | EP | disclosed |
| US-5976535-A | ADMINISTERING A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND STREPTAVIDIN; AND SUBSEQUENTLY ADMINISTERING A SECOND CONJUGATE COMPRISING A CYTOKINE AND BIOTIN, REDUCING THE ENDOGENOUS BIOTIN LEVEL | NEORX CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0733066-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0695194-A4 | IMPROVED DETECTION AND THERAPY OF LESIONS WITH BIOTIN/AVIDIN POLYMER CONJUGATES | IMMUNOMEDICS INC (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1998058078-A1 | METHOD OF DETERMINING THE ENZYMATIC ACTIVITY OF THE BLOOD COAGULATION FACTOR XIII USING PURIFIED FIBRIN MONOMER AS A SUBSTRATE | KOREA GREEN CROSS CORPORATION (KR) | 1998-12-23 | — | — | WO | disclosed |
| EP-0733066-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0695194-A1 | IMPROVED DETECTION AND THERAPY OF LESIONS WITH BIOTIN/AVIDIN POLYMER CONJUGATES | Immunomedics, Inc. (US) | 1996-02-07 | — | — | EP | disclosed |
| US-5482698-A | Detection and therapy of lesions with biotin/avidin polymer conjugates | IMMUNOMEDICS, INC. (US) | 1996-01-09 | — | — | US | disclosed |
| WO-1995015979-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1994023759-A1 | IMPROVED DETECTION AND THERAPY OF LESIONS WITH BIOTIN/AVIDIN POLYMER CONJUGATES | IMMUNOMEDICS, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183654-A1 | METHOD FOR SELECTING HYBRIDOMA CELLS FROM A PLURALITY OF HYBRIDOMA CELLS BY MEANS OF A BIRA EXPRESSION VECTOR | BTD, BIRC5, HLCS | TDP1 3241/4885HLCS 3/4885CNR1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.